Robert D. Hubbard

1.2k citations

24 papers · 900 indexed · h-index 16

Impact in

Organic Chemistry top 5%
- Synthetic Organic Chemistry Methods
- Catalytic Alkyne Reactions
- Cyclopropane Reaction Mechanisms
- Catalytic C–H Functionalization Methods
- Asymmetric Synthesis and Catalysis
- Synthesis and biological activity
- Carbohydrate Chemistry and Synthesis
Biotechnology top 10%

Papers in

Organic Chemistry 11
- Synthetic Organic Chemistry Methods 5
- Asymmetric Synthesis and Catalysis 3
Endocrinology, Diabetes and Metabolism 6
- Growth Hormone and Insulin-like Growth Factors 6

Co-authors: Paul A. WenderLei ZhangGabriel G. Gamber Sayee G. Hegde Benjamin L. Miller Son M. Pham Scott R. Horner Susan L. Mooberry
Journals: Bioorganic & Medicinal Chemistry Letters (6 papers)Journal of the American Chemical Society (4 papers)Molecular Cancer Therapeutics (2 papers)Proceedings of the National Academy of Sciences (2 papers)Pure and Applied Chemistry (1 paper)
Partner nations: United States United Kingdom Japan

In The Last Decade

Robert D. Hubbard

24 papers receiving 889 citations

Peers

Countries citing papers authored by Robert D. Hubbard

Since Specialization

Citations

This map shows the geographic impact of Robert D. Hubbard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert D. Hubbard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert D. Hubbard more than expected).

Fields of papers citing papers by Robert D. Hubbard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert D. Hubbard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert D. Hubbard. The network helps show where Robert D. Hubbard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Robert D. Hubbard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert D. Hubbard Line = papers co-authored together Robert D. Hubbard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1 Proceedings of the National Academy of Sciences ·脇隆博, Aida Razi, Robert D. Hubbard, Richard M. Walsh, Shaun Rawson, Geng Tian, Daniel Finley, John Hanna	2023	6
2	Cationic lipids percentage and processing temperature are critical in designing siRNA lipid nanoparticles Journal of drug targeting ·Stauffer Al, Yemin Liu, R.I. FAKHRAZIEV, T. E. C., Leiming Li, Yu Shen, Robert D. Hubbard, William E. Kohlbrenner, Ji Zhou, Zeynep Üstün, John W. Skoug	2012	4
3	A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors RNA ·Xiaoyu Lin, Leiming Li, Rongqi Wang, Denise Wilcox, Xiaobin Zhao, R.I. FAKHRAZIEV, Xiaoli Huang, O. Ubuara-Frank, Prasad Dande, Carol K. Wada, Robert D. Hubbard, 周家瑜, Stephen W. Fesik, Yu Shen	2011	16
4	Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Steve Fidanze, Scott Erickson, Gary T. Wang, Robert A. Mantei, Richard F. Clark, Bryan K. Sorensen, Nwe Y. BaMaung, Peter Kovar, Eric F. Johnson, Kerren K. Swinger, Kent D. Stewart, Qian Zhang, Lora A. Tucker, William N. Pappano, Julie L. Wilsbacher, Jieyi Wang, George S. Sheppard, Randy L. Bell, Steven K. Davidsen, Robert D. Hubbard	2010	50
5	Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases Bioorganic & Medicinal Chemistry Letters ·Gary T. Wang, Robert A. Mantei, Robert D. Hubbard, Julie L. Wilsbacher, Qian Zhang, Lora A. Tucker, Xiaoming Hu, Peter Kovar, Eric F. Johnson, Donald J. Osterling, Jennifer J. Bouska, Jieyi Wang, Steven K. Davidsen, Randy L. Bell, George S. Sheppard	2010	22
6	Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605 BMC Cancer ·William N. Pappano, Paul Jung, Jonathan A. Meulbroek, Yichun Wang, Robert D. Hubbard, Qian Zhang, W. H. Olson, Niru B. Soni, Eric F. Johnson, George S. Sheppard, Cherrie K. Donawho, Fritz G. Buchanan, Steven K. Davidsen, Randy L. Bell, Jieyi Wang	2009	14
7	Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Alex G. Waterson, Kimberly G. Petrov, Keith R. Hornberger, Robert D. Hubbard, Yuanqi Bei, 钟升, Hamilton D. Dickson, Thomas R. Caferro, Kevin W. Hinkle, Kirk L. Stevens, Scott H. Dickerson, David W. Rusnak, Glenn Spehar, Edgar R. Wood, Robert Griffin, David Uehling	2009	33
8	Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases Bioorganic & Medicinal Chemistry Letters ·Robert D. Hubbard, Nwe Y. BaMaung, Steve Fidanze, Scott Erickson, Abdollah Fazelli, Julie L. Wilsbacher, Qian Zhang, Lora A. Tucker, Xiaoming Hu, Peter Kovar, Donald J. Osterling, Eric F. Johnson, Jennifer J. Bouska, Jieyi Wang, Steven K. Davidsen, Randy L. Bell, George S. Sheppard	2009	17
9	Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation Journal of Biological Chemistry ·Julie L. Wilsbacher, Qian Zhang, Lora A. Tucker, Robert D. Hubbard, George S. Sheppard, Nwe Y. BaMaung, Steve Fidanze, Gary T. Wang, Xiaoming Hu, Steven K. Davidsen, Randy L. Bell, Jieyi Wang	2008	22
10	Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines Bioorganic & Medicinal Chemistry Letters ·Robert D. Hubbard, Scott H. Dickerson, Е. В. Дадаян, Robert Griffin, Michael J. Reno, Keith R. Hornberger, David W. Rusnak, Edgar R. Wood, David Uehling, Alex G. Waterson	2008	29
11	Severe hyperglycemia induced by kinase inhibitors of insulin-like growth factor-1 receptor in mice is associated with inhibition of insulin receptor signaling in skeletal muscle Molecular Cancer Therapeutics ·Xiaoming Hu, Julie L. Wilsbacher, Donald J. Osterling, Jennifer J. Bouska, George S. Sheppard, Robert D. Hubbard, Nwe Y. BaMaung, Steve Fidanze, Steven K. Davidsen, Reinhard Stolpe, Jieyi Wang	2007	1
12	Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR) Bioorganic & Medicinal Chemistry Letters ·Robert D. Hubbard, Nwe Y. BaMaung, Abdollah Fazelli, Qian Zhang, Peter Kovar, Donald J. Osterling, Xiaoming Hu, Julie L. Wilsbacher, Eric F. Johnson, Jennifer J. Bouska, Jieyi Wang, Randy L. Bell, Steven K. Davidsen, George S. Sheppard	2007	18
13	Advances towards the Development of ATP‐Competitive Small‐Molecule Inhibitors of the Insulin‐Like Growth Factor Receptor (IGF‐IR) ChemMedChem ·Robert D. Hubbard, Julie L. Wilsbacher	2006	8
14	Conformational and Structural Analysis of a ter‐Cyclopentane Scaffold for Molecular Recognition European Journal of Organic Chemistry ·Peter C. Gareiss, Prakash B. Palde, Robert D. Hubbard, Benjamin L. Miller	2006	1
15	Microtubule-stabilizing agents based on designed laulimalide analogues Proceedings of the National Academy of Sciences ·Susan L. Mooberry, Aphylla Planifolia Harp, Lotfi Daoud, Sayee G. Hegde, Robert D. Hubbard, Lei Zhang, Paul A. Wender	2004	60
16	Regioselective and diastereoselective synthesis of highly substituted cyclopentanes Tetrahedron ·Robert D. Hubbard, Benjamin L. Miller	2003	2
17	Synthesis and Biological Evaluation of (−)-Laulimalide Analogues Organic Letters ·Paul A. Wender, Sayee G. Hegde, Robert D. Hubbard, Lei Zhang, Susan L. Mooberry	2003	41
18	Toward the ideal synthesis. New transition metal-catalyzed reactions inspired by novel medicinal leads Pure and Applied Chemistry ·Paul A. Wender, F. Christopher Bi, Gabriel G. Gamber, Francis Gosselin, Robert D. Hubbard, Marc J. C. Scanio, Robert Sun, Travis J. Williams, Lei Zhang	2002	117
19	Total Synthesis of (−)-Laulimalide Journal of the American Chemical Society ·Paul A. Wender, Sayee G. Hegde, Robert D. Hubbard, Lei Zhang	2002	75
20	Lewis Acid Catalyzed Diels−Alder Reactions of Highly Hindered Dienophiles The Journal of Organic Chemistry ·Robert D. Hubbard, Benjamin L. Miller	1998	12

About Robert D. Hubbard

Robert D. Hubbard is a scholar working on Organic Chemistry, Endocrinology, Diabetes and Metabolism, Biochemistry, Cancer Research and Oncology, having authored 24 papers that have together received 900 indexed citations. Recurring topics across this work include Growth Hormone and Insulin-like Growth Factors (6 papers), Synthetic Organic Chemistry Methods (5 papers), HER2/EGFR in Cancer Research (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Cancer, Hypoxia, and Metabolism (3 papers), RNA Interference and Gene Delivery (3 papers), Advanced biosensing and bioanalysis techniques (3 papers) and Asymmetric Synthesis and Catalysis (3 papers). The work is most often cited by research in Organic Chemistry (653 citations), Biotechnology (54 citations), Oncology (130 citations), Molecular Biology (308 citations) and Pharmacology (67 citations). Robert D. Hubbard has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Paul A. Wender, Lei Zhang, Gabriel G. Gamber, Sayee G. Hegde, Benjamin L. Miller, Son M. Pham, Scott R. Horner, Susan L. Mooberry, Travis J. Williams and Robert Sun. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of the American Chemical Society, Molecular Cancer Therapeutics, Proceedings of the National Academy of Sciences and Pure and Applied Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact